News
Capital‑market reactions were sharp. Shares fell 25.3 % to $17.55 immediately after the earnings announcement, and subsequently dropped 54 % following a postponement of the 10‑Q filing pending an accounting review. In pre‑market trading after the outlook cut, the stock fell 40 % to $14.20, contributing to a year‑to‑date decline of 43.8 %. The SEC h...
10/02/2026 | Kyndryl Holdings, Inc.
The company reiterated its fiscal‑year‑2026 outlook, projecting adjusted pre‑tax income of $575 million to $600 million, an adjusted EBITDA margin of approximately 17.5 %, and free cash flow of $325 million to $375 million—down from the prior guidance of $550 million. Kyndryl also reversed its previous 1 % growth outlook, now forecasting a constant...
10/02/2026 | Kyndryl Holdings, Inc.
Kyndryl reported third‑quarter fiscal‑2026 revenue of $3.86 billion, a 3.1 % year‑on‑year increase that fell short of the Zacks Consensus Estimate of $3.91 billion. Adjusted EBITDA was $696 million, down 1 % YoY, while adjusted pre‑tax income rose 5 % to $168 million. Net income for the period stood at $57 million and free cash flow (non‑GAAP) was...
10/02/2026 | Kyndryl Holdings, Inc.
Meanwhile, the company’s share price has fallen 93.8 % over the past five years to $26.43. Valuation analysis indicates a significant undervaluation. A discounted cash‑flow model suggests a 74.1 % discount, estimating an intrinsic value of $102.24 per share. Price‑to‑sales stands at 0.91×, well below peer and industry averages, and a fair‑ratio est...
10/02/2026 | RingCentral, Inc.
On February 19, 2026, RingCentral will report its fourth‑quarter and full‑year 2025 results after the market close. A conference call will follow at 2:00 PM Pacific Time, with a live webcast available on the investor‑relations website. Analysts expect the release to shed light on revenue growth, profitability, and customer acquisition trends, and i...
10/02/2026 | RingCentral, Inc.
RingCentral, Inc. (NYSE: RNG) was named a Top Provider in Metrigy Research’s 2025 MetriStar UCaaS Report. The company earned the highest overall customer sentiment score and performed above average in voice quality, security, value, analytics, AI capabilities, and ease of use. Customers reported the highest productivity improvements, the highest re...
10/02/2026 | RingCentral, Inc.
In comparison, Paymentus (PAY) and Insulet (PODD) have posted robust sales growth and profitability. Paymentus’s market share has expanded, while Insulet’s free cash‑flow margin has increased by 32.6 percentage points over the past five years, offering attractive investment prospects relative to their peers.
10/02/2026 | DoubleVerify Holdings, Inc.
DoubleVerify (DV) is a cash‑rich firm with a trailing 12‑month free cash‑flow margin of 19.2 %. Its sales growth is projected to slow to 9.3 % over the next 12 months as competitive pressure and higher spending on sales and marketing erode operating margins. DV’s forward price‑to‑sales ratio remains high at 2×. Despite these headwinds, its stock pr...
10/02/2026 | DoubleVerify Holdings, Inc.
Leerink notes that Moderna’s strengthened solvency could intensify the IP dispute, leaving legal and royalty outcomes as a continuing risk. Consequently, analysts focus on the 2026 batoclimab catalyst as the central lever for potential upside. The long‑term revenue growth and net profit margin inputs remain unchanged, while the projected future P/E...
09/02/2026 | Roivant Sciences Ltd.
Roivant Sciences’ valuation model remains anchored at a $27.0 per‑share fair value, but the required return has risen to a discount rate of 7.54%, tightening the price target narrative. The shift follows the rescheduling of batoclimab Phase 3 readouts to 2026 and the persistence of litigation over Moderna royalties. Analysts such as Citi’s Samantha...
09/02/2026 | Roivant Sciences Ltd.